Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.

Medicine and Dentistry

• Diabetic Nephropathy 100%
• End Stage Renal Disease 33%
• Glycemic Control 33%
• Glucagon-Like Peptide-1 Agonist 33%
• Complication of Diabetes 33%
• Patient with Diabetes 33%
• Dipeptidyl Peptidase-4 Inhibitor 33%
• Diabetes 33%
• Albumin 33%
• Glycemic 33%
• Urinary System 33%
• Cardiovascular System 33%
• Sodium-Glucose Cotransporter 2 Inhibitors 33%

Nursing and Health Professions

• Diabetic Nephropathy 100%
• Accident Prevention 66%
• Glucagon Like Peptide 1 Receptor Agonist 33%
• Patient with Diabetes 33%
• Dipeptidyl Peptidase IV Inhibitor 33%
• End Stage Renal Disease 33%
• Sodium Glucose Cotransporter 2 Inhibitor 33%
• Cardiovascular System 33%
• Albumin 33%
• Efficacy 33%
• Glycemic Control 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetic Nephropathy 100%
• End Stage Renal Disease 33%
• Glucagon Like Peptide 1 Receptor Agonist 33%
• Dipeptidyl Peptidase IV Inhibitor 33%
• Albumin 33%
• sodium glucose cotransporter-2 inhibitors 33%